JP2012143232A5 - - Google Patents

Download PDF

Info

Publication number
JP2012143232A5
JP2012143232A5 JP2012021947A JP2012021947A JP2012143232A5 JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5 JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
seq
monoclonal antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012021947A
Other languages
English (en)
Japanese (ja)
Other versions
JP5420688B2 (ja
JP2012143232A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012021947A priority Critical patent/JP5420688B2/ja
Priority claimed from JP2012021947A external-priority patent/JP5420688B2/ja
Publication of JP2012143232A publication Critical patent/JP2012143232A/ja
Publication of JP2012143232A5 publication Critical patent/JP2012143232A5/ja
Application granted granted Critical
Publication of JP5420688B2 publication Critical patent/JP5420688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012021947A 2005-12-20 2012-02-03 抗ilt7抗体 Active JP5420688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
JP2005366465 2005-12-20
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007551124A Division JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Publications (3)

Publication Number Publication Date
JP2012143232A JP2012143232A (ja) 2012-08-02
JP2012143232A5 true JP2012143232A5 (cg-RX-API-DMAC7.html) 2013-04-25
JP5420688B2 JP5420688B2 (ja) 2014-02-19

Family

ID=38188642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体
JP2012021947A Active JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Country Status (29)

Country Link
US (6) US8084585B2 (cg-RX-API-DMAC7.html)
EP (4) EP2532681B1 (cg-RX-API-DMAC7.html)
JP (2) JP5020828B2 (cg-RX-API-DMAC7.html)
KR (3) KR101585532B1 (cg-RX-API-DMAC7.html)
CN (5) CN105111311B (cg-RX-API-DMAC7.html)
AU (1) AU2006328470B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0620141B1 (cg-RX-API-DMAC7.html)
CA (2) CA2634116C (cg-RX-API-DMAC7.html)
CY (3) CY1114227T1 (cg-RX-API-DMAC7.html)
DK (3) DK2913343T3 (cg-RX-API-DMAC7.html)
ES (3) ES2699428T3 (cg-RX-API-DMAC7.html)
HK (1) HK1218126A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20130494T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039865T2 (cg-RX-API-DMAC7.html)
IL (1) IL192266A (cg-RX-API-DMAC7.html)
LT (1) LT2913343T (cg-RX-API-DMAC7.html)
ME (1) ME02111B (cg-RX-API-DMAC7.html)
MX (1) MX2008007682A (cg-RX-API-DMAC7.html)
NZ (3) NZ569910A (cg-RX-API-DMAC7.html)
PL (3) PL1964852T3 (cg-RX-API-DMAC7.html)
PT (3) PT2913343T (cg-RX-API-DMAC7.html)
RS (2) RS53752B1 (cg-RX-API-DMAC7.html)
RU (2) RU2456298C2 (cg-RX-API-DMAC7.html)
SG (2) SG170749A1 (cg-RX-API-DMAC7.html)
SI (3) SI2532681T1 (cg-RX-API-DMAC7.html)
TR (1) TR201816574T4 (cg-RX-API-DMAC7.html)
UA (1) UA97946C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007072866A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200805850B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
EP2563393B1 (en) 2010-04-26 2016-06-08 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
CA2831426C (en) 2011-04-01 2023-02-21 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
US9567391B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
PL2828284T3 (pl) 2012-03-20 2019-11-29 Biogen Ma Inc Przeciwciała neutralizujące wirus jc
EP2890715B1 (en) * 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
CN104755498B (zh) 2012-08-31 2019-06-18 伊缪诺金公司 用于检测叶酸受体1的诊断测定和试剂盒
US9637547B2 (en) 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3270965B1 (en) * 2015-03-18 2020-05-06 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
SI3313884T1 (sl) * 2015-06-29 2021-04-30 Immunogen, Inc. Protitelesa proti CD123 ter njihovi konjugati in derivati
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2018006249A (es) * 2015-11-19 2018-11-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-emr2 y metodos de uso.
CN109069211B (zh) 2016-01-26 2022-04-29 网络牙科(美国)公司 自动牙科治疗系统
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP3426298A4 (en) * 2016-03-10 2019-11-27 Viela Bio, Inc. ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF
EA201892225A1 (ru) * 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス, インコーポレイテッド グリカン相互作用化合物および使用の方法
EP3675898A4 (en) 2017-08-30 2021-09-01 Phanes Therapeutics, Inc. ANTI-LAG-3 ANTIBODIES AND THEIR USES
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
CA3082409A1 (en) * 2017-11-17 2019-05-23 Merck Sharp & Dohme Corp. Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
KR20200103751A (ko) * 2017-12-20 2020-09-02 라디뮨 테라퓨틱스 인코포레이티드 센트린-1에 대한 항체, 이의 제조 방법, 및 용도
US11655295B2 (en) * 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
US20210251721A1 (en) 2018-05-10 2021-08-19 Cyberdontics (Usa), Inc. Automated dental drill
US20200017596A1 (en) * 2018-05-10 2020-01-16 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
EP4013510A1 (en) 2019-08-12 2022-06-22 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
EP4069288A4 (en) * 2019-12-06 2024-01-17 Viela Bio, Inc. TREATMENT METHODS USING ILT7 BINDING PROTEINS
AU2021261257A1 (en) 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof
CN116801810A (zh) 2020-09-03 2023-09-22 网络牙科(美国)公司 用于牙齿解剖结构的cna分析的方法和装置
EP4333877A1 (en) 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
KR20250042166A (ko) 2022-07-27 2025-03-26 비엘라 바이오, 인크. 면역글로불린-유사 전사체 7(ilt7) 결합 단백질을 포함하는 제형
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
KR20250160358A (ko) * 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
ATE412433T1 (de) * 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
EP2332579A3 (en) * 2000-02-10 2011-09-21 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
US7485713B2 (en) * 2001-10-13 2009-02-03 Asterion Limited Polypeptides comprising growth hormone receptor extracellular domain and glycosylphosphatidylinositol
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Similar Documents

Publication Publication Date Title
JP2012143232A5 (cg-RX-API-DMAC7.html)
JP2014526898A5 (cg-RX-API-DMAC7.html)
JP2018536393A5 (cg-RX-API-DMAC7.html)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2017114866A5 (cg-RX-API-DMAC7.html)
JP2020536488A5 (cg-RX-API-DMAC7.html)
JP2013538057A5 (cg-RX-API-DMAC7.html)
JP2012501669A5 (cg-RX-API-DMAC7.html)
JP2014516540A5 (cg-RX-API-DMAC7.html)
JP2014524733A5 (cg-RX-API-DMAC7.html)
JP2011527899A5 (cg-RX-API-DMAC7.html)
JP2014534207A5 (cg-RX-API-DMAC7.html)
JP2012501670A5 (cg-RX-API-DMAC7.html)
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
JP2020501532A5 (cg-RX-API-DMAC7.html)
CN104086652B (zh) 抗o型口蹄疫病毒特异性单域抗体及其重组表达载体
JP2014518883A5 (cg-RX-API-DMAC7.html)
JP2012012402A5 (cg-RX-API-DMAC7.html)
JP2018504105A5 (cg-RX-API-DMAC7.html)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2016516400A5 (cg-RX-API-DMAC7.html)
RU2017113732A (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)
JP2014511680A5 (cg-RX-API-DMAC7.html)
JP2015508056A5 (cg-RX-API-DMAC7.html)